Skip to main content

Regeneron Pharmaceuticals guidance

  • REGN · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$959.12+0.71%Close 17 Nov 2026 · Market value $102.6B

In its results release of 30 Oct 2026 (Q3 FY2026), Regeneron Pharmaceuticals gave 5 forecasts in figures, among them gross margin (gaap) of 80% for FY2026.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 30 Oct 2026

MeasurePeriodGuidanceAs stated
Gross margin · GAAPFY202680%GAAP gross margin on net product sales 80%
Gross margin · AdjustedFY202686%Non-GAAP gross margin on net product sales 86%
Capital expendituresFY2026$1.05B to $1.10BCapital expenditures $1.050-$1.100 billion
Tax rate · GAAPFY202614%GAAP effective tax rate 14%
Tax rate · AdjustedFY202615%Non-GAAP effective tax rate 15%

Source: the company's earnings release.

Guidance against results above 1 · within 1 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
Gross margin · GAAPFY202680%Raised twice, lowered once—To come
Gross margin · AdjustedFY202686%Raised twice—To come
Capital expendituresFY2026$1.05B to $1.10BRaised once, lowered twice—To come
Tax rate · GAAPFY202614%Raised twice—To come
Tax rate · AdjustedFY202615%Raised twice—To come
Capital expendituresFY2025$850M to $890MRaised once, lowered once$898MAbove the range
Tax rate · GAAPFY202514%Raised once13.88%Within the range

REGN in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.